Market Closed -
London S.E.
11:35:24 2024-05-07 EDT
|
5-day change
|
1st Jan Change
|
308
GBX
|
-0.65%
|
|
+3.53%
|
+8.83%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,356
|
4,555
|
6,141
|
2,698
|
3,074
|
3,298
|
-
|
-
|
Enterprise Value (EV)
1 |
3,165
|
4,147
|
5,156
|
2,085
|
2,870
|
3,099
|
2,992
|
3,055
|
P/E ratio
|
-31.5
x
|
-34.9
x
|
-28.7
x
|
-7.43
x
|
30
x
|
-28.5
x
|
600
x
|
34
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.4
x
|
20
x
|
17.2
x
|
6.33
x
|
3.67
x
|
4.84
x
|
3.95
x
|
3.23
x
|
EV / Revenue
|
15.4
x
|
18.2
x
|
14.5
x
|
4.89
x
|
3.42
x
|
4.55
x
|
3.58
x
|
2.99
x
|
EV / EBITDA
|
-22.4
x
|
-21.8
x
|
-16.1
x
|
-5.23
x
|
108
x
|
-20.6
x
|
-57.2
x
|
154
x
|
EV / FCF
|
-35.4
x
|
-
|
-23.4
x
|
-6.83
x
|
15.4
x
|
-15.1
x
|
-120
x
|
54.5
x
|
FCF Yield
|
-2.83%
|
-
|
-4.28%
|
-14.6%
|
6.5%
|
-6.61%
|
-0.83%
|
1.83%
|
Price to Book
|
11.7
x
|
9.46
x
|
6.28
x
|
4.52
x
|
4.29
x
|
1.67
x
|
1.64
x
|
1.35
x
|
Nbr of stocks (in thousands)
|
665,965
|
724,205
|
856,470
|
845,074
|
853,410
|
853,644
|
-
|
-
|
Reference price
2 |
5.039
|
6.290
|
7.170
|
3.193
|
3.602
|
3.863
|
3.863
|
3.863
|
Announcement Date
|
20-03-03
|
21-03-04
|
22-03-03
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
204.9
|
228
|
356.1
|
426.4
|
838
|
681.4
|
835.8
|
1,022
|
EBITDA
1 |
-141.4
|
-190.6
|
-321.1
|
-399
|
26.58
|
-150.1
|
-52.35
|
19.9
|
EBIT
1 |
-146.4
|
-196.7
|
-328.3
|
-407.7
|
18.38
|
-153.1
|
-43.91
|
30.86
|
Operating Margin
|
-71.45%
|
-86.27%
|
-92.19%
|
-95.61%
|
2.19%
|
-22.47%
|
-5.25%
|
3.02%
|
Earnings before Tax (EBT)
1 |
-141.1
|
-189.7
|
-215.7
|
-410.4
|
58.31
|
-142.4
|
-34.55
|
52.25
|
Net income
1 |
-106
|
-125.7
|
-194.6
|
-360.8
|
100.8
|
-108.9
|
-5.786
|
85.38
|
Net margin
|
-51.75%
|
-55.15%
|
-54.66%
|
-84.62%
|
12.03%
|
-15.98%
|
-0.69%
|
8.36%
|
EPS
2 |
-0.1600
|
-0.1800
|
-0.2500
|
-0.4300
|
0.1200
|
-0.1355
|
0.006440
|
0.1137
|
Free Cash Flow
1 |
-89.48
|
-
|
-220.6
|
-305.3
|
186.6
|
-204.7
|
-24.98
|
56.04
|
FCF margin
|
-43.67%
|
-
|
-61.95%
|
-71.59%
|
22.27%
|
-30.04%
|
-2.99%
|
5.48%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
702.15%
|
-
|
-
|
281.67%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
185.2%
|
-
|
-
|
65.64%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-03
|
21-03-04
|
22-03-03
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
102.7
|
106.8
|
121.2
|
157.4
|
198.8
|
202
|
224.4
|
532.9
|
305.1
|
321.9
|
349.3
|
404.9
|
414.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-78.16
|
-118.5
|
-143.7
|
-184.6
|
-196.8
|
-210.9
|
111.7
|
-93.28
|
-65.2
|
-79.6
|
-61.44
|
-67.52
|
Operating Margin
|
-
|
-73.21%
|
-97.77%
|
-91.34%
|
-92.86%
|
-97.38%
|
-94.02%
|
20.95%
|
-30.57%
|
-20.25%
|
-22.79%
|
-15.18%
|
-16.28%
|
Earnings before Tax (EBT)
1 |
-
|
-76.58
|
-113.2
|
-140.4
|
-75.29
|
-200.6
|
-209.8
|
-
|
-78.78
|
-39.7
|
-103.1
|
-
|
-
|
Net income
1 |
-
|
-49.69
|
-76.04
|
-102.4
|
-92.25
|
-162.9
|
-198
|
-
|
-67.77
|
-52.6
|
-64.3
|
-
|
-
|
Net margin
|
-
|
-46.55%
|
-62.73%
|
-65.07%
|
-46.41%
|
-80.61%
|
-88.24%
|
-
|
-22.21%
|
-16.34%
|
-18.41%
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-03
|
20-07-30
|
21-03-04
|
21-07-28
|
22-03-03
|
22-08-01
|
23-02-28
|
23-07-31
|
24-02-28
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
190
|
408
|
985
|
613
|
204
|
199
|
306
|
243
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-89.5
|
-
|
-221
|
-305
|
187
|
-205
|
-25
|
56
|
ROE (net income / shareholders' equity)
|
-31.3%
|
-32.6%
|
-26.5%
|
-45.2%
|
13.8%
|
-13.6%
|
-2.77%
|
11%
|
ROA (Net income/ Total Assets)
|
-21.3%
|
-21.1%
|
-18.6%
|
-30%
|
7.88%
|
-9.66%
|
-3.88%
|
3.85%
|
Assets
1 |
498.6
|
594.6
|
1,048
|
1,201
|
1,280
|
1,127
|
149.1
|
2,217
|
Book Value Per Share
2 |
0.4300
|
0.6700
|
1.140
|
0.7100
|
0.8400
|
2.310
|
2.350
|
2.860
|
Cash Flow per Share
2 |
-0.1200
|
-0.0900
|
-0.2600
|
-0.3200
|
0.2500
|
-0.1300
|
-0.0300
|
0.0900
|
Capex
1 |
8.57
|
7.95
|
16.4
|
36.7
|
32.6
|
26.1
|
24.2
|
27.5
|
Capex / Sales
|
4.18%
|
3.49%
|
4.61%
|
8.6%
|
3.89%
|
3.83%
|
2.89%
|
2.7%
|
Announcement Date
|
20-03-03
|
21-03-04
|
22-03-03
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Last Close Price
3.863
USD Average target price
5.386
USD Spread / Average Target +39.41% Consensus |
1st Jan change
|
Capi.
|
---|
| +8.83% | 3.3B | | +33.43% | 700B | | +26.43% | 569B | | -5.12% | 358B | | +19.59% | 330B | | +4.89% | 287B | | +14.32% | 236B | | +5.79% | 202B | | -9.49% | 197B | | +4.26% | 161B |
Other Pharmaceuticals
|